Oyster Point Pharma, Inc. (OYST)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

202 CARNEGIE CENTER PRINCETON, NJ 08540

Oyster Point Pharma, Inc. operates as a biopharmaceutical company. The Company discovers and develops novel therapies to treat ocular surface diseases. Oyster Point Pharma serves patients in the United States.

Data as of 2020-06-27
Market Cap730.948 Million Shares Outstanding25.692 Million Avg 30-day Volume190.776 Thousand
P/E Ratio Dividend Yield EPS-10.81
Price/Sales Price cash flow ratio Price free cash flow ratio-15.5
Book Value4.75 Price to Tangible Book6.1 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low41.37 / 13.26 Stddev
View SEC Filings from OYST instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 5 1 (0.07%)
13F Filers holding this stock: 45 14 (0.92%)
Aggregate 13F shares on 03/31/2020: 14.084 Million 5.616 Million
Aggregate 13F shares on 12/31/2019: 13.568 Million 2.007 Million
Percent change: 3.80% 179.87%
Funds creating new positions: 9 7
Funds Adding to an existing position: 11 3
Funds closing out their position: 5 2
Funds reducing their position: 14 2
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OYST (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OYST BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

178.6 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BEHBAHANI ALI

  • Director
0 2020-07-01 2

SNISARENKO JOHN

  • Director
0 2020-06-18 3

KERINS PATRICK J

  • 10% Owner
8,097,725 2020-06-10 1

ACKERMANN MICHAEL

  • Director
292,729 2020-06-08 4

MURRAY MARK ANTHONY

  • Director
115,047 2020-06-08 3

LINK WILLIAM J PHD

  • Director
2,976,728 2020-06-08 3

TSAI BENJAMIN

  • Director
6,600 2020-06-08 2

WEISNER AIMEE S

  • Director
29,725 2020-06-08 3

OZAWA CLARE

  • Director
3,572,146 2020-06-08 3

BARRIS PETER J

  • Director
6,420 2020-05-27 1

INVOPPS GP IV, L.L.C.

INVOPPS IV, L.P.

INVOPPS IV US, L.P.

LAINOVIC SACHA

  • Director
  • 10% Owner
2,768,586 2020-05-19 3

NAU JEFFREY PRESIDENT AND CEO

  • Officer
  • Director
0 2020-02-03 3

LOCHNER DANIEL CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-03 3

OYSTER POINT PHARMA I, LLC

  • 10% Owner
955,392 2019-11-04 2

VERSANT VENTURE CAPITAL VI, L.P.

VERSANT VENTURES VI GP, L.P.

VERSANT VENTURES VI GP-GP, LLC

VERSANT VANTAGE I, L.P.

VERSANT VANTAGE I GP, L.P.

VERSANT VANTAGE I GP-GP, LLC

VERSANT VENTURES IV, LLC

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

  • 10% Owner
5,580,282 2019-11-04 1

KLEINER PERKINS CAUFIELD & BYERS XIV, LLC

KPCB XIV ASSOCIATES, LLC

KPCB XIV FOUNDERS FUND, LLC

  • 10% Owner
367,987 2019-11-04 1

VIDA VENTURES, LLC

  • 10% Owner
963,468 2019-11-04 2

KKR FUND HOLDINGS L.P.

KRAVIS HENRY R

ROBERTS GEORGE R

KKR MANAGEMENT LLC

KKR & CO. INC.

KKR GROUP HOLDINGS CORP.

KKR FUND HOLDINGS GP LTD

1,039,622 2019-11-04 1

FALCON VISION LLC

KKR HEALTHCARE STRATEGIC GROWTH FUND L.P.

KKR HCSG GP LLC

KKR ASSOCIATES HCSG L.P.

1,039,622 2019-11-04 1

NEW ENTERPRISE ASSOCIATES 14, L.P.

SONSINI PETER W.

BARRIS PETER J

NEA PARTNERS 14, L.P.

NEA 14 GP, LTD

BASKETT FOREST

FLORENCE ANTHONY A. JR.

MOTT DAVID M

SANDELL SCOTT D

  • 10% Owner
5,925,287 2019-11-04 1

NEW ENTERPRISE ASSOCIATES 14, L.P.

SONSINI PETER W.

NEA PARTNERS 14, L.P.

NEA 14 GP, LTD

BASKETT FOREST

FLORENCE ANTHONY A. JR.

MOTT DAVID M

SANDELL SCOTT D

  • 10% Owner
322,458 2019-10-30 1

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

OZAWA CLARE - Director

2020-06-08 A 6,600 a 6,600 3,572,146.00 direct

TSAI BENJAMIN - Director

2020-06-08 A 6,600 a 6,600 6,600.00 direct

ACKERMANN MICHAEL - Director

2020-06-08 A 14,805 a 152,162 292,729.00 direct

BEHBAHANI ALI - Director

2020-06-08 A 6,600 a 6,600 6,600.00 direct

LINK WILLIAM J PHD - Director

2020-06-08 A 6,600 a 6,600 2,976,728.00 direct

WEISNER AIMEE S - Director

2020-06-08 A 6,600 a 29,725 29,725.00 direct

MURRAY MARK ANTHONY - Director

2020-06-08 A 6,600 a 115,047 115,047.00 direct

INVOPPS GP IV, L.L.C. - Director - > 10% Owner see footnotes

INVOPPS IV, L.P. - Director - > 10% Owner see footnotes

INVOPPS IV US, L.P. - Director - > 10% Owner see footnotes

LAINOVIC SACHA - Director - > 10% Owner see footnotes

2020-05-19 P 59,178 $28.00 a 917,768 2,768,586.00 indirect

INVOPPS GP IV, L.L.C. - Director - > 10% Owner see footnotes

INVOPPS IV, L.P. - Director - > 10% Owner see footnotes

INVOPPS IV US, L.P. - Director - > 10% Owner see footnotes

LAINOVIC SACHA - Director - > 10% Owner see footnotes

2020-05-19 P 119,393 $28.00 a 1,850,818 2,768,586.00 indirect
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments